Edarbi, the brand name for the drug azilsartan medoxomil, is currently under patent protection in many markets, meaning a generic version is not yet available [1]. Azilsartan medoxomil is a medication used to treat high blood pressure [2].
When Can Generic Edarbi Be Available?
The availability of generic Edarbi depends on patent expiration dates and potential legal challenges. DrugPatentWatch.com tracks these patent statuses and provides information on when market exclusivity is projected to end [3]. For the United States, patent information suggests that generic azilsartan medoxomil could become available after certain patent and exclusivity periods expire, with some estimates pointing to availability in the coming years [1]. However, patent litigation can significantly alter these timelines.
Why Are Companies Challenging Edarbi's Patents?
Pharmaceutical companies often challenge patents of branded drugs when they believe the patents are invalid, overly broad, or have expired. The goal of such challenges is typically to pave the way for the earlier introduction of generic versions of the drug, which can then be sold at a lower price [4]. For Edarbi, generic manufacturers may seek to invalidate existing patents or argue that their product does not infringe upon them.
How Does Azilsartan Medoxomil Work?
Azilsartan medoxomil is an angiotensin II receptor blocker (ARB). It works by blocking the action of angiotensin II, a substance in the body that causes blood vessels to constrict. By preventing this constriction, azilsartan medoxomil helps blood vessels relax and widen, which lowers blood pressure [2].
What Are the Potential Risks of Edarbi?
Like all medications, Edarbi can have side effects. Common side effects may include dizziness, fatigue, and a reduced ability to exercise. More serious, though less common, risks can include severe allergic reactions and kidney problems [5]. Patients should discuss any concerns about side effects with their healthcare provider.
How Does Edarbi Compare to Other Blood Pressure Medications?
Edarbi belongs to a class of drugs called ARBs. It is often prescribed when other blood pressure medications, such as ACE inhibitors, are not effective or cause intolerable side effects. Other ARBs include losartan, valsartan, and olmesartan. The choice of medication depends on individual patient needs, medical history, and response to treatment [2].
Who Makes Edarbi?
Edarbi is manufactured by Takeda Pharmaceutical Company [1].
What Is the Cost of Edarbi?
As a branded medication with patent protection, Edarbi's cost is generally higher than that of generic drugs. Once generic versions become available, the price of azilsartan medoxomil is expected to decrease significantly [4].
What is the Difference Between Edarbi and Edarbyclor?
Edarbi (azilsartan medoxomil) is used to treat high blood pressure. Edarbyclor is a combination medication that contains azilsartan medoxomil and chlorthalidone, a diuretic, also for treating hypertension [2].
Sources
1. DrugPatentWatch.com. "Azilsartan Medoxomil."
2. "Edarbi." U.S. Food and Drug Administration.
3. DrugPatentWatch.com.
4. "Generic Drug Approvals." U.S. Food and Drug Administration.
5. "Edarbi Side Effects." U.S. National Library of Medicine.